Table 1. Clinical characteristics of patients by statin group.

	Statin users (n=44) No. (%)	Statin non-users (n=282) No. (%)	p-value
Demographics
Male sex	24 (54.5)	165 (58.5)	.620
Age, median (IQR) years	64 (56-74)	57 (43-70)	.006
Comorbid conditions
Chronic renal disease	18 (40.9)	63 (22.3)	.008
Dialysis	6 (13.6)	17 (6)	.067
Diabetes mellitus	22 (50)	67 (23.8)	<.001
COPD	10 (22.7)	57 (20.2)	.710
Chronic heart disease	25 (56.8)	61 (21.6)	<.001
Cerebrovascular disease	8 (18.2)	40 (14.2)	.505
Liver disease	2 (4.5)	52 (18.4)	.021
Malignancy	16 (36.4)	111 (39.4)	.692
Stem cell transplantation	2 (4.5)	20 (7.1)	.394
Graft versus Host disease	0 (0)	8 (2.8)	.273
Solid organ transplantation	6 (13.6)	26 (9.2)	.364
HIV infection	0 (0)	14 (5)	.131
Risk factors
ICU stay	20 (45.5)	132 (46.8)	.802
Mechanical ventilation	18 (40.9)	103 (36.5)	.636
Total parenteral nutrition	13 (29.5)	88 (31.2)	.768
Vasopressor therapy	10 (22.7)	78 (27.7)	.430
Previous surgery	23 (52.3)	112 (39.7)	.120
Catheter placement (>48h)	41 (93.2)	248 (87.9)	.360
Urinary catheter	32 (72.7)	130 (46.1)	.002
Neutropenia	0 (0)	42 (14.9)	.006
Chemotherapy	4 (9.1)	58 (20.6)	.070
Radiotherapy	1 (2.3)	9 (3.2)	.735
Corticosteroid therapy	15 (34.1)	133 (47.2)	.122
Prior antibiotic therapy	41 (93.2)	256 (90.8)	.801
Immunosuppressive therapy	10 (22.7)	65 (23)	.953
Antifungal prophylaxis	2 (4.5)	35 (12.4)	.120
Clinical characteristics (at candidemia diagnosis)
Fever	38 (86.4)	213 (75.5)	.169
Hypotension	26 (59.1)	125 (44.3)	.293
Vasopressor therapy requirement	16 (36.4)	83 (29.4)	.402
Acute renal failure	18 (40.9)	81 (28.7)	.127
Confusion	20 (45.5)	98 (34.8)	.217
APACHE II, median (IQR)	18 (11-23)	16 (11-23)	.365